

David H. Winslow, M.D., F.C.C.P.
Diplomat American Board of Sleep Medicine
Chest Medicine Associates/Sleep Medicine Specialists/Kentucky Research Group
1169 Eastern Parkway, Suites 2243, 2266, 3310, & 3357
Louisville, KY 40217
July 1979 - Present



Personal

Birthdate: February 3, 1947
Married, wife Rita
Two children; Darran and Brian

Professional Training

University of Cincinnati Medical Center
Cincinnati, Ohio
Internship, Medical Rotating
June 1973-June-1974

University Hospital
Louisville, Kentucky
Residency in Medicine
July 1974-June 1976

University of Louisville Medical Center
Louisville, Kentucky
Fellowship in Pulmonary Diseases
July 1976 – June 1978

Education

University of Louisville
Louisville, Kentucky
Medical Doctor, June 1973

Murray State University
Murray, Kentucky
Bachelor of Science in Biology, Chemistry
Graduated August 1969

Employment

Wolford and Dame Group Practice
Mixed Internal Medicine, June 1978 – May 1979

Chest Medicine Associates, PSC
Pulmonary and Sleep Medicine, June 1979 - Present

Licensing

Kentucky Medical License: No. 17414
American Board of Internal Medicine- June 1977
American Board of Internal Medicine in Pulmonary Diseases- June 1979
American Sleep Disorders Association Board Certified- Diplomate- June 1988

Medical Societies

Member NAASO – The Obesity Society
Member American Thoracic Society
Member American Medical Association
Member Kentucky Thoracic Society
Member Kentucky Medical Association
Member Jefferson County Medical Society
Member Kentucky Sleep Society
Fellow American College of Chest Physicians
Fellow American College of Physicians
Fellow American Academy of Sleep Medicine

Faculty Positions

Associate Clinical Professor
Department of Medicine
University on Louisville School of Medicine

Directorships

Medical Director, Sleep Disorders Center

Norton Audubon Hospital

1983-Present

Medical Director, Chest Medicine Associates, DBA Sleep Medicine Specialists

1996-Present

Medical Director, Chest Medicine Associates, DBA Sleep Medicine Specialists

Research Division

1999-Present

Medical Director and President, Kentucky Research Group

2005-Present

Teaching

Residency Training Program

Norton Audubon Hospital

1984-Present

Professional Service

Norton Audubon Hospital

Chairman- Ethics Committee

1998-Present

Kentucky Sleep Society

Board Member

1998-2004

President 2001

Training

“Investigator Training for Medical Research”

Sponsored by: University of Rochester, School of Medicine & Dentistry

Strong Memorial Hospital

Western Institutional Review Board

Chicago, Illinois

August 31, 2001

Research

Pharmaceutical research, Principle Investigator:

Merck: A Double-Blind, Parallel, Placebo-Controlled, Multicenter, Polysomnographic Study of the Effects of L-759274 and Zolpidem in Patients with Chronic Insomnia. 1999.

Sepracor 190-046: A Randomized Double-Blind, Placebo-Controlled Parallel Study of the Efficacy and Safety of (S)-Zopiclone in the Treatment of Adult Subjects with Primary Insomnia. 2001.

Sepracor 190-047: A Randomized, Double-Blind, Placebo-Controlled Parallel, Two-Week Objective Efficacy and Safety Study of Esopiclone in Elderly Subjects with Primary Insomnia. 2001-2002.

Takeda 375-005: An Efficacy, Safety, and Dose Response Study of TAK-375 in Subjects with Chronic Insomnia. 2001-2002.

GlaxoSmithKline 101468/191: A 12 Week, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS). 2002.

Sanofi-Synthelabo EFC4529: Comparison of efficacy and safety of Zolpidem-MR 12.5mg and placebo in patients with primary insomnia. A double-blind, randomized, placebo controlled, parallel group study. 2002.

Neurocrine NBI34060-MR-0212: A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of a modified release formulation of NBI-34060 in elderly primary insomnia patients with sleep maintenance difficulties. 2003.

Takeda 375-022: A phase III, Open-label, fixed dose study to determine the safety of long term administration of TAK-375 in subjects with chronic Insomnia. 2002.

GlaxoSmithKline 101468/243: A 52 Week, Open-label extension study of the Long-term safety and tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS). 2003.

Orphan Medical, Inc. OMC-SXB-15: A Randomized, double blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Zyrem (sodium oxybate) with Placebo for the Treatment of Narcolepsy. 2003.

Orphan Medical, Inc. OMC-SXB-19: An Open Label, Multi-Center Safety Trial studying the Effects of Orally Administered Xyrem (sodium oxybate). 2003.

Orphan Medical, Inc. OMC-SXB-22: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (sodium oxybate) and Modafinil with Placebo in the Treatment of Daytime Sleepiness in Narcolepsy. 2003 – 2004.

Takeda 01-03-TL-375-038: A Phase II Safety Study of TAK-375 in Subjects with Mild to Moderate Chronic Obstructive Pulmonary Disease. 2003.

GlaxoSmithKline 101468/249: A 12 Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS). 2003-2004.

Sanofi-Synthelabo EFC5202: Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients with Primary Insomnia. A Double-Blind, Randomized, Placebo- Controlled, Three Way Cross-Over Study. 2003.

Altana Pharma BY217/M2-023: A Randomized, Controlled Study of Roflumilast (250 mcg and 500 mcg) Versus Placebo in Patients with Asthma. A 24-week, multicenter, multinational, double-blind, parallel group clinical study. 2004

Cephalon Inc, CEP-10953 C10953/3021/AP/MN: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome. 2004

Cephalon, Inc. C10953/3024/ES/MN:A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/day) Extension Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder. 2004-2006.

Aventis M100907C/2004: A North American, 4-Week, Multicenter, Phase IIB Double-Blind, Placebo-Controlled, Randomized, Multiple Dose, Parallel- Group Study of the Efficacy and Safety of 0.5 mg, 1.0 mg, and 2.0 mg M100907 Tablets in the treatment of Sleep Maintenance Insomnia. 2004-2005.

Sanofi-Synthelabo LTE5407: Evaluation of the Long-Term Efficacy and Safety of Zolpidem-MR 12.5mg Compared to Placebo, When Both are Administered Over a Long-Term Period “As Needed”, in Patients With Chronic Primary Insomnia. (A Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase IIIb Clinical Study). 2004

Pfizer A9001243: A Study To Define The Non-Restorative Sleep Population. 2004 – 2005

Merck 002-00: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-night Polysomnographic Study of MK-0928 in Elderly Patients with Primary Insomnia. 2004-2007.

Merck 004-00: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-night Polysomnographic Study of MK-0928 in Adult Patients with Primary Insomnia. 2004-2006.

Oscient OS-001/FORCE: A Phase IV, Stratified, Randomized, Prospective, Unblinded, Active-control Trial of Factive Versus Biaxin XL for the Treatment of Community-acquired Pneumonia and Versus Amoxicillin/clavulante for the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis, and any subsequent amendments provided by Sponsor. 2004-2007.

GlaxoSmithKline 100013: A 12 Week, Double-Blind, Placebo Controlled, Twice Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in

Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage. 2004

Takeda 01-04-TL-375-041: A Randomized, Double-Blind, Placebo Controlled Study to Assess the Subjective Response to Treatment With Ramelteon (TAK-375) in Adult Subjects With Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data. 2005

Neurocrine NBI-34060-MR-0501: A Phase III, Randomized, Double-Blind, Placebo Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Primary Insomnia Patients with Sleep Maintenance Difficulties. 2005

Somaxon SP-0501: A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of Doxepin HCl in Primary Insomnia Patients with Sleep Maintenance Difficulties. 2005

Schwarz SP792: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome. 2005-2006

Kyowa 6002-US-201: A Phase 2, Double-Blind, Placebo Controlled, Randomized Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/day KW-6002 (Istradefylline) in Subjects with Restless Legs Syndrome. 2005-2006

GlaxoSmithKline 1001468/205: A 12 Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome. 2005

Somaxon SP-0503: A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Assess the Long Term Efficacy and Safety of Doxepin HCl in Primary Elderly Insomnia Patients with Sleep Maintenance Difficulties. 2005-2006.

Takeda EC302: A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia. 2005 – 2006.

Cephalon C10953/3046/ES/US: A Short-Term (8-Week) Open-Label Study, Followed by a Long-Term Evaluation, to Assess Patient Reported Outcomes with Armodafinil Treatment (150 to 250 mg/day) For Excessive Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS). 2005-2006

Sanofi-Aventis LTE6262: Efficacy and Safety of Eplivanserin 5mg/day on Sleep Maintenance Insomnia: a 12-Week multicenter, Randomized, Double-Blind, Placebo-Controlled Study Followed by an open Treatment Phase Extension with Eplivanserin for a 40 Week Period. 2006.

XenoPort, Inc. XP052: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients with Restless Legs Syndrome. 2006-2007.

Schwarz SP793: An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment with Transdermal Rotigotine in Subjects with Idiopathic Restless Legs Syndrome. 2006 – 2007.

Merck 022: A Multicenter, Randomized, Double-Blind, “Factorial” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia. 2006.

Merck 024: A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B Verses Atorvastatin in Patients With Mixed Hyperlipidemia. 2006.

Sanofi-Aventis EFC6220: Efficacy and Safety of Eplivanserin 5mg/day on Sleep Maintenance Insomnia: a 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. 2006-2007.

Takeda 01-05-TL-375-068: A Study of the Safety of Ramelteon with Moderate to Severe Chronic Obstructive Pulmonary Disease. 2006.

Merck 022-01: A Multicenter, Randomized, Double-Blind, “Factorial” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia. 2006–2007.

Novartis CVEA489A2302: An 8-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/Amlopidine Compared to Valsartan/HCTZ, Valsartan/Amlopidipine, and HCTZ/Amlodipine in Patients With Moderate to Severe Hypertension. 2006-2007.

Merck 315: A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium Alone or in Combination with Hydrochlorothiazide versus Placebo in Obese Patients with Elevated Systolic and Diastolic Blood Pressure. 2006 – 2007.

XenoPort, Inc. XP055: An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients with Restless Legs Syndrome. 2006-Ongoing.

Takeda 01-05-TL-375-067: A Phase2, Double-blind, randomized, placebo-controlled, parallel-group, Multi-center Proof-of-Concept Study to evaluate the safety and efficacy of Ramelteon taken in combination with Doxepin for the treatment of subjects with Chronic Insomnia. 2006-2007.

GlaxoSmithKline 103660: A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients with Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep. 2006-2007.

Merck 023: a Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin. 2006 – 2007.

Xenoport XP-081: A Randomized, Double-Blind, Placebo-Controlled Dose Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 in Patients with Restless Legs Syndrome. 2007.

Merck V512–003: Validation of Patient Reported Outcome Measures for Influenza Disease for Use in Phase II POC/Phase III Flu Peptide Vaccine Program. 2007.

Xenoport XP083: A Randomized, Double-Blind, Active- and Placebo Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-Treated Patients with Restless Legs Syndrome. 2007.

Pfizer A5351019: A 2 year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of CP-945,598 in the Treatment of Obese Subjects. 2007-2008.

Organon 176001: A two-week, double-blind, placebo-controlled, randomized, parallel group, efficacy and safety, out-patient trial with Org 50081 in patients with chronic primary insomnia. 2007-2008.

Organon 176004: Fifty-Two weeks, open-label extension trial to evaluate safety and efficacy of Org 50081 in outpatients with chronic primary insomnia who completed Clinical Trial Protocol 176001 or 176002. 2007–Ongoing.

Sanofi–Aventis LTE6673/Sams: Efficacy and Safety of 2mg/day of M100907 on Sleep Maintenance Insomnia with a Sub-Study of the effect of M100907 on Stable Type II Diabetes Mellitus: a One Year, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study. 2007-2009.

Takeda 01-06-TL-375-071: Randomization, Double-Blind, Placebo-Controlled Study to Assess Whether the Administration of Ramelteon Could Facilitate the Discontinuation of Zolpidem (Ambien) >10mg Therapy in Subjects with Chronic Insomnia. 2007-2008.

Sanofi–Aventis EFC6072/Nocturne: Efficacy and Safety of 2mg/day of M100907 on Sleep Maintenance Insomnia: a 6-week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study. 2007-2008.

Merck 079: Randomized, Double-Blind, Active-Comparator, Clinical Trial to Study the Efficacy and Safety of MK-0431A for the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM). 2007 - 2008.

Vanda VP-VEC-162-3104: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 (20mg/day and 50 mg/day) in the Treatment of Primary Insomnia. 2007 – 2008.

Vivus OB-301: A Phase III, Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of VI-0521 to Placebo and Their Single-Agent Phentermine and Topiramate Constituents for the Treatment of Obesity in Adults. 2007 – 2008.

Merck 015: A Multicenter, Randomized, Double-Blind, Double-Dummy, placebo and Modafinil Controlled, 3-Period Crossover, Adaptive Dose Design study to Determine the Safety and Efficacy of MK-0249 in Treating Excessive daytime Sleepiness in Patients with Obstructive Sleep Apnea Using Nasal continuous Positive Airway Pressure (nCPAP) Therapy. 2008 – 2009.

Arena APD125-007: A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of APD125 in Patients with Primary Insomnia Characterized by Difficulty Maintaining Sleep. 2008.

Pfizer A0081183: Randomized, Double-Blind, 6 Week Study of Pregabalin in Subjects with Restless Leg Syndrome. 2008 - 2009.

Sanofi EFC6909: A Double-Blind, Randomized, 12-Month, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy and Safety of AVE5530 25mg/day and AVE5530 50mg/day in Patients with Primary Hypercholesterolemia. 2008 – 2009.

VIVUS OB-204: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of VI-0521 for the Treatment of Obstructive Sleep Apnea/Hypopnea Syndrome in Obese Adults. 2008 – 2009.

Sanofi EFC10844/ECLIPSE: Efficacy and Safety of Eplivanserin 5mg/day in Insomnia Characterized by Sleep Maintenance difficulties: A 6-Week, Randomized, Double-Blind, Placebo-Controlled, Polysomnography Study. 2008 - 2009

Pfizer A9001380: Refinement of Patient Reported Outcomes Instruments in Subjects with Insomnia Characterized by Non Restorative Sleep. 2008 – 2009.

Takeda AD4833_402: A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for 1 Year of Treatment 2009 – Ongoing.

Pfizer A0081186: Randomized, double-blind 12-month Study of Pregabalin in Subjects with Restless Legs Syndrome. 2009-Ongoing.

Ventus C009-Aero: A prospective, multicenter parallel group, sham-controlled, randomized, double-blinded clinical trial to compare the safety and effectiveness of the Provent Professional Sleep Apnea Therapy device to sham for the non-invasive treatment of obstructive sleep apnea. 2009.

Sanofi-Aventis EFC6014 GetGoalM: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Multicenter, 24 week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients with Type-2 Diabetes not Adequately Controlled with Metformin. 2009-Ongoing.

Cephalon C10953-3067/ES/MN: A 12-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage, Study to Evaluate the Efficacy and Safety of Armodafinil (50, 150, and 250 mg/day) as Treatment for Patients With Excessive Sleepiness Associated With Mild to Moderate Closed Traumatic Brain Injury. 2009-Ongoing.

Ventus C009E-Aero: A prospective, multicenter, single arm, open-label extension study to evaluate the long-term durability of treatment response and safety of the Provent Professional Sleep Apnea Therapy Devices for the non-invasive treatment of obstructive sleep apnea - hypopnea. 2009 – Ongoing.

Pfizer A8801015: A Randomized Phase 2, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study of PF-03654745 as a Daily Treatment for Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy. 2009-Ongoing.

Pfizer A0081165: Effects of Pregabalin on Sleep Maintenance in Subjects with Fibromyalgia Syndrome and Sleep Maintenance Disturbance: Randomized, Placebo-Controlled, 2-way Crossover Polysomnography Study. 2009 – Ongoing.

Merck 009: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia. 2009 – Ongoing.

Publications

Carlson, H., Winslow, D., Kastan, L. and Yam, L. T. Bone marrow necrosis. Archives of Internal Medicine 137: 863-866, 1977.

Winslow, D. H. Exercise induced asthma. Journal of the Kentucky Medical Association 76: 271-274, 1978.

Browman, C. P. and Winslow, D. H. Sleep apnea syndrome. Louisville Medicine 31: 19-21, September 1983.

Browman, C. P. and Winslow, D. H. Insomnia and family practice. Kentucky Academy of Family Physicians Journal 29: 14-15, October, 1983.

Giradet, R. E., Goodin, R. R., Johnson, S. G., Shanahan, P.T., Melo, J. C., Winslow, D. H., Woo, D., Epstein, W. M., Watson, K., Steltzer, G., Burke, G., Rhine, G., Lansing, A. Heart transplantation at the Humana Heart Institute International. Journal of the Kentucky Medical Association 84: 261 – 267, 1986.

Browman, C. P. and Winslow, D. H. Clinical aspects of insomnia. Comprehensive Therapy, 12: 29 – 35, October 1986.

Dogramji, K., Breuninger, W. M., Browman, C. P., Gaddy, J. R., Muehlbach, M. J., Schweitzer, P. K., Walsh, J. K., and Winslow, D. H. Triazolam treatment of periodic leg movements during sleep. Sleep Research 17:38, 1988

Browman, C. P. and Winslow, D. H. Determination of sleep latency in polysomnographic evaluations of daytime somnolence in patients with sleep apnea and patients with narcolepsy. Clinical Electroencephalography 20: 45 - 48, 1989.

Browman, C. P., Newman, J. C., and Winslow, D. H. Nasal CPAP therapy for obstructive sleep apnea syndrome: Determinants of long-term compliance. Sleep Research 18: 206, 1989.

Browman, C. P., Unruh, M. M., and Winslow, D. H. Differential diagnosis of the hypersomnolent patient. Sleep Research in press.

Browman, C. P., Ostrander, S. E., Starz, K. E., and Winslow, D. H. Effect of two formulations of triazolam in induced sleep-onset insomnia. Sleep Research 18: 47, 1989.

Browman, C. P., Winslow, D. H., Starz, K. E., Roehrs, T. A., Harris, A. E., Rosenthal, L. D., and Roth, T. Effects of triazolam, a new formulation of triazolam, and placebo on the sleep of patients with chronic insomnia. Sleep Research 18: 48, 1989.

App, W. E., Boatwright, G. W., Ostrander, S. E., Unruh, M. M., and Winslow, D. H. Disorder of excessive daytime somnolence: A case series of 1,000 patients. Journal of the Kentucky Medical Association 88: 393-396, 1990.

Newman, J. C., Unruh, M. M., and Winslow, D. H. Nasal CPAP Therapy for Obstructive Sleep Apnea Syndrome: Determinants of Long Term Compliance. 1989 Annual Meeting Abstracts, Association of Professional Sleep Societies, 3rd Annual Meeting. June 1989.

Winslow, D. H. Sleep Hypopnea Syndrome. 1990 Annual Meeting Abstracts, Kentucky Thoracic Society Scientific Conference on Pulmonary Disease, March 1990.

Winslow, D. H. Cocaine Abuse Presented as Narcolepsy. 1990 Annual Meeting Abstracts, Kentucky Thoracic Society Scientific Conference on Pulmonary Disease, March 1990.

Richard Allen, PhD; Philip M. Becker, MD; Richard Bogan, MD; Markus Schmidt, MD, PhD; Clete A. Kushida, MD, PhD; June M. Fry, MD, PhD, J. Steven Poceta; David Winslow, MD. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep Journal of Sleep and Sleep Disorders Research August 2004;27:907-914

Wetzler RG, Linfield K, Doerr NW, Cole JD, Winslow DH
Factors associated with initial adjustment to Continuous Positive Airway Pressure (CPAP). Sleep, Volume 29, Abstract Supplement, 2006 A167
Wetzler RG, Linfield KJ, Fulkerson EE, Schwarz RM, Kostiwa IM, Price DS, Winslow, DH Effectiveness of a Cognitive-Behavioral Treatment Program for Chronic Insomnia Sleep Journal of Sleep and Sleep Disorders Research, Volume 32, Abstract Supplement, 2009 0821

Kostiwa IM, Wetzler RG, Fulkerson EE, Schwarz RM, Price DS, Winslow, DH
Sleep Improves in Patients Discontinuing Medication Use With CBT-I Sleep Journal of Sleep and Sleep Disorders Research, Volume 32, Abstract Supplement, 2009 0830

Wetzler RG, Fulkerson EE, Linfield KJ, Schwarz RM, Winslow DH Could Depression be Over-Diagnosed in a Sleep Disordered Population? Differential Diagnosis and Treatment Considerations *Sleep Journal of Sleep and Sleep Disorders Research*, Volume 32, Abstract Supplement, 2009 1080

Fulkerson EE, Wetzler RG, Linfield KJ, Schwarz RM, Winslow DH Personality Characteristics of Patients Seeking Treatment at a Behavioral Sleep Medicine Clinic *Sleep Journal of Sleep and Sleep Disorders Research*, Volume 32, Abstract Supplement, 2009 1083

Revised: 05 Feb 2010 kjm